Samsung releases its first biosimilar drug in U.S.
Danielle Haynes, United Press International Writer SEOUL, South Korea (UPI) -- Electronics giant Samsung made its first foray into U.S. pharmaceuticals Monday when it joined efforts with Merck to release a lower-cost version of a rheumatoid arthritis drug. Samsung Bioepis, a subsidiary of the South Korean producer of televisions and smartphones, and Merck Biosimilars released Renflexis, a version of Johnson & Johnson's Remicade. The U.S. Food and Drug Administration gave approval in April to the drug, which the companies said would be sold for […]
